Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Keloids - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Keloids - Pipeline Review, H1 2015', provides an overview of the Keloids's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Keloids - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Keloids - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Keloids Overview 6 Therapeutics Development 7 Pipeline Products for Keloids - Overview 7 Pipeline Products for Keloids - Comparative Analysis 8 Keloids - Therapeutics under Development by Companies 9 Keloids - Therapeutics under Investigation by Universities/Institutes 10 Keloids - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Keloids - Products under Development by Companies 13 Keloids - Products under Investigation by Universities/Institutes 14 Keloids - Companies Involved in Therapeutics Development 15 Delenex Therapeutics AG 15 RestorGenex Corporation 16 RXi Pharmaceuticals Corporation 17 Vida Therapeutics Inc. 18 Keloids - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 CIGB-128 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CM-101 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 DLX-1008 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 koebnerisin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 P-529 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 psoriasin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RXI-109 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 V-2248 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Keloids - Recent Pipeline Updates 41 Keloids - Dormant Projects 47 Keloids - Discontinued Products 48 Keloids - Product Development Milestones 49 Featured News & Press Releases 49 Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 49 Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 49 Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 50 Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 51 Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 51 Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables Number of Products under Development for Keloids, H1 2015 7 Number of Products under Development for Keloids - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Keloids - Pipeline by Delenex Therapeutics AG, H1 2015 15 Keloids - Pipeline by RestorGenex Corporation, H1 2015 16 Keloids - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 17 Keloids - Pipeline by Vida Therapeutics Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Keloids Therapeutics - Recent Pipeline Updates, H1 2015 41 Keloids - Dormant Projects, H1 2015 47 Keloids - Discontinued Products, H1 2015 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
